This result is similar to the observation that oral Fe attenuates severity of disease in patients with SLC39A14 or SLC30A10 deficiency, although the Fe levels used in our study were much greater than therapeutic doses. The gene discussed is SLC30A10; the disease is hyperinsulinemic hypoglycemia, familial, 4.